MicroPort CardioFlow Medtech Corporation (HKG:2160)

Hong Kong · Delayed Price · Currency is HKD

1.200

-0.060 (-4.76%)

Jun 18, 2026, 4:08 PM HKT

-75.51% (1Y)

Market Cap	1.53B -20.8%
Revenue (ttm)	444.00M +12.3%
Net Income	-146.48M
EPS	-0.30
Shares Out	1.27B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,441,404
Open	1.240
Previous Close	1.260
Day's Range	1.150 - 1.260
52-Week Range	1.150 - 8.450
Beta	0.28
Analysts	Strong Buy
Price Target	7.07 (+489.17%)
Earnings Date	Aug 28, 2026

About HKG:2160

MicroPort CardioFlow Medtech Corporation, together with its subsidiaries, researches, develops, manufactures, and sells medical devices for the treatment of structural heart disease and cardiac rhythm management in China, Europe, the Middle East, Africa, Asia, North America, and internationally. The company offers VitaFlow, a transcatheter aortic valve system; VitaFlow Liberty, a transcatheter aortic valve retrievable and controllable bend delivery system; Alwide, a plus valve balloon dilation catheter; AccuSniper, a double-layer balloon dilati... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2009

Employees 1,415

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2160

Full Company Profile

Financial Performance

In 2025, HKG:2160's revenue was $57.04 million, an increase of 12.28% compared to the previous year's $50.81 million. Losses were -$18.82 million, 170.9% more than in 2024.

Financial numbers in USD Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2160 stock is "Strong Buy." The 12-month stock price target is $7.07, which is an increase of 489.17% from the latest price.

Price Target

$7.07

(489.17% upside)

Analyst Consensus: Strong Buy

Stock Forecasts